Mark S. Blumenkranz
Academic Appointments
- Professor - Med Center Line, Ophthalmology
- Member, Bio-X
Key Documents
Contact Information
-
Clinical Offices
Byers Eye Institute at Stanford 2452 Watson Court MC 5353 Palo Alto, CA 94303 Tel Work (650) 723-6995 Fax (650) 565-8297Practices at Stanford Hospital and Clinics and Lucile Packard Children's Hospital
- Academic Offices
Personal Information Email Tel (650) 725-0231Administrative Contact Clarissa Saluta Chair Administrator Email Tel Work 650-725-0231Not for medical emergencies or patient use
Professional Overview
Clinical Focus
- Ophthalmology
- Macular and Vitreoretinal Diseases
Administrative Appointments
- Professor and Chairman, Stanford University School of Medicine - Ophthalmology (1997 - present)
Honors and Awards
- Senior Honor Award, American Academy of Ophthalmology (2004)
- Lifetime Achievement Award, American Academy of Ophthalmology (2008)
Professional Education
| Residency: | Stanford University School of Medicine CA (1979) |
| Residency: | Stanford University School of Medicine CA (1977) |
| Internship: | Stanford University School of Medicine CA (1976) |
| Board Certification: | Ophthalmology, American Board of Ophthalmology (1980) |
| Fellowship: | University Of Miami - School of Medicine FL (1980) |
| Medical Education: | Brown University - School of Medicine RI (1975) |
Graduate & Fellowship Program Affiliations
Industry Relationships
Stanford is committed to ethical and transparent interactions with our industrial and other commercial partners. It is our policy to disclose payments (exclusive of travel support) from, and/or equity in, companies or other commercial entities to Stanford faculty of $5,000 or more in total value, as well as any equity in a privately held company, when the faculty member also has institutional responsibilities related to his or her interactions with the company. View Full Information
Scientific Focus
Current Research Interests
Clinical Interest and Research
My primary areas of interest are in the diagnosis, medical and surgical treatment of vitreal retinal diseases. These principally include age-related macular degeneration and other diseases of the macula, and tractional syndromes, diabetic retinopathy, and complex forms of retinal detachment. I have been interested in the development of novel technology to diagnose and treat these diseases, including new forms of imaging, laser delivery systems, other microsurgical tools, and new drugs and drug delivery systems that inhibit new blood vessel growth, scarring and intraocular inflammation. I have been actively involved in translational research in the laboratory as well as technology transfer associated with that research for a variety of new therapies that have received FDA clearance and been introduced into clinical practice over the past 30 years.
Administrative and Community Service
I have served on the Board of Directors of a variety of voluntary education and service organizations, including the Corporation of Brown University, multiple scientific advisory boards and various philanthropic and research organizations.
Publications
- Longterm cultures of the aged human RPE do not maintain epithelial morphology and high transepithelial resistance. Graefes Arch Clin Exp Ophthalmol. 2012; (2): 313-5
- Panretinal photocoagulation for proliferative diabetic retinopathy. Am J Ophthalmol. 2012; (4): 780-1; author reply 781-2
- Tennis partners. Retina. 2012: S12-4
- Critical appraisal of the clinical utility of the dexamethasone intravitreal implant (Ozurdex) for the treatment of macular edema related to branch retinal vein occlusion or central retinal vein occlusion. Clin Ophthalmol. 2011: 1043-9
- Femtosecond laser capsulotomy. J Cataract Refract Surg. 2011; (7): 1189-98
- Fifty years of ophthalmic laser therapy. Arch Ophthalmol. 2011; (12): 1613-9
Help
Trial Administration